[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341549-105":59,"doc-detail-341549-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-pet-surrogate-signature-for-the-interrogation-of-the-metabolic-status-of-breast-cancers","A PET-Surrogate Signature for the Interrogation of the Metabolic Status of Breast Cancers","","Metabolic alterations in breast cancers enable diagnostic, prognostic, and therapeutic opportunities, exemplified by 18F-FDG PET imaging that depends on tumor glucose uptake. By integrating transcriptomic analysis of breast cancer samples stratified by FDG-PET, the study identifies a 54-gene PETsign signature that recapitulates FDG uptake. PETsign independently predicts clinical outcomes in luminal breast cancers across cohorts and stages, including early disease. Mechanistically, transcriptomic and metabolomic profiling indicates enhanced glycolytic dependence and reduced fatty-acid oxidation reliance. Coamplification of PETsign genes and strong involvement of CXCL8 and EGFR signaling support causal roles in pathogenesis, positioning PETsign as a molecular surrogate for FDG-PET to inform management.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-pet-surrogate-signature-for-the-interrogation-of-the-metabolic-status-of-breast-cancers/341549/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-pet-surrogate-signature-for-the-interrogation-of-the-metabolic-status-of-breast-cancers/341549.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is PETsign in this study?","Question",{"text":113,"@type":114},"PETsign is a 54-gene transcriptomic signature identified from breast cancer samples stratified by FDG-PET that recapitulates FDG uptake.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How is PETsign linked to clinical prognosis?",{"text":118,"@type":114},"PETsign is independently prognostic for clinical outcomes in luminal breast cancers, with prognostic power stable across independent cohorts and disease stages.",{"name":120,"@type":111,"acceptedAnswer":121},"What metabolic and signaling mechanisms does PETsign reflect?",{"text":122,"@type":114},"PETsign predicts enhanced glycolytic dependence and reduced reliance on fatty acid oxidation, and it highlights CXCL8 and EGFR signaling pathways that shift cells toward a glycolytic phenotype.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},341549,1790289076,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","RESEARCH ARTICLE  \n[www.advancedscience.com](www.advancedscience.com)  \nA PET-Surrogate Signature for the Interrogation of the Metabolic Status of Breast Cancers  \nStefano Confalonieri, Bronislava Matoskova, Rosa Pennisi, Flavia Martino, Agnese De Mario, Giorgia Miloro, Francesca Montani, Luca Rotta, Mahila Esmeralda Ferrari,  \nLaura Gilardi, Francesco Ceci, Chiara Maria Grana, Rosario Rizzuto, Cristina Mammucari, Pier Paolo Di Fiore,* and Letizia Lanzetti*  \nMetabolic alterations in cancers can be exploited for diagnostic, prognostic, and therapeutic purposes. This is exempliﬁed by 18F-ﬂuorodeoxyglucose (FDG)-positron emission tomography (FDG-PET), an imaging tool that relies on enhanced glucose uptake by tumors for diagnosis and staging. By performing transcriptomic analysis of breast cancer (BC) samples from patients stratiﬁed by FDG-PET, a 54-gene signature (PETsign) is identiﬁed that recapitulates FDG uptake. PETsign is independently prognostic of clinical outcome in luminal BCs, the most common and heterogeneous BC molecular subtype, which requires improved stratiﬁcation criteria to guide therapeutic decision-making. The prognostic power of PETsign is stable across independent BC cohorts and disease stages including the earliest BC stage, arguing that PETsign is an ab initio metabolic signature. Transcriptomic and metabolomic analysis of BC cells reveals that PETsign predicts enhanced glycolytic dependence and reduced reliance on fatty acid oxidation. Moreover, coampliﬁcation of PETsign genes occurs frequently in BC arguing for their causal role in pathogenesis. CXCL8 and EGFR signaling pathways feature strongly in PETsign, and their activation in BC cells causes a shift toward a glycolytic phenotype. Thus, PETsign serves as a molecular surrogate for FDG-PET that could inform clinical management strategies for BC patients.  \ntumor evolution and disease progression. [1] Metabolic plasticity is exempliﬁed by aerobic glycolysis, commonly referred to asthe Warburg eﬀect. [2] This phenomenon involves the avid uptake of glucose by cancer cells and its conversion to lactate even in the presence of oxygen. [3] Traditionally, the Warburg eﬀect was viewed as a strategy adopted by cancer cells to compensate for a deﬁcit in energy production by mitochondria. [4]. However, a more recent interpretation is that it serves to enhance glycolytic ﬂux, thereby increasing the availability of metabolic intermediates to fuel anabolic pathways. [3,5]  \nThe Warburg eﬀect can be indirectly studied in vivo using a variety of methods, the most common being 18F-ﬂuorodeoxyglucose (FDG)-positron emission tomography (FDG-PET) . This imaging method is widely used in oncology for diagnosis, staging, re-staging after therapy, and follow-up. It relies on the use of the glucose-derivative radiotracer, FDG, which is avidly taken by tumors  \n1. Introduction  \nThe ability of tumors to adapt their metabolism to match speciﬁc needs is a recognized hallmark of cancer, crucial in shaping  \ncharacterized by increased glucose metabolism. PET imaging evaluates several parameters that provide diﬀerent measurements ofthe extent ofFDG uptake within a particular region (e.g., the tumor) . Among them, the maximum standardized uptake  \nS. Confalonieri, B. Matoskova, G. Miloro, F. Montani, L. Rotta, M. E. Ferrari, L. Gilardi, F. Ceci, C. M. Grana, P. P. Di Fiore IEO  \nEuropean Institute of Oncology IRCCS Via Ripamonti 435, Milan 20141, Italy E-mail: pierpaolo.diﬁ[ore@ieo.it](ore@ieo.it)  \nThe ORCID identiﬁcation number(s) for the author(s) of this article  \ncan be found under [https://doi.org/10.1002/advs.202308255](https://doi.org/10.1002/advs.202308255)[ ](https://doi.org/10.1002/advs.202308255)© 2024 The Authors. Advanced Science published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nDOI: 10.1002","cbCailVWgSyhGzZN","https://ap.wps.com/l/cbCailVWgSyhGzZN","pdf",3228001,14,"English","# Introduction\n# Metabolic imaging and the Warburg effect\n## FDG-PET and SUVmax\n## Breast cancer subtypes and clinical stratification","[{\"question\":\"What is PETsign in this study?\",\"answer\":\"PETsign is a 54-gene transcriptomic signature identified from breast cancer samples stratified by FDG-PET that recapitulates FDG uptake.\"},{\"question\":\"How is PETsign linked to clinical prognosis?\",\"answer\":\"PETsign is independently prognostic for clinical outcomes in luminal breast cancers, with prognostic power stable across independent cohorts and disease stages.\"},{\"question\":\"What metabolic and signaling mechanisms does PETsign reflect?\",\"answer\":\"PETsign predicts enhanced glycolytic dependence and reduced reliance on fatty acid oxidation, and it highlights CXCL8 and EGFR signaling pathways that shift cells toward a glycolytic phenotype.\"}]","A PET-Surrogate Signature for the Interrogation of the Metabolic Status of Breast Cancers | PDF",1790042503,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bccf21d251b3fa0528c5a414f47211ee.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e211cfbc46e0bc862fe921b2ed9016f8.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50e34d3cd518b5232c5adc9494fed4a5.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b1053ea25139687c0a818fe96add141.webp",980,1287]